Cargando…
Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021
COVID-19 vaccine effectiveness by product (two doses Comirnaty, Spikevax or Vaxzevria and one of Janssen), against infection ranged from 50% (95% CI: 42 to 57) for Janssen to 86% (70 to 93) for Vaxzevria-Comirnaty combination; among ≥ 60 year-olds, from 17% (−26 to 45) for Janssen to 68% (48 to 80)...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Centre for Disease Prevention and Control (ECDC)
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485582/ https://www.ncbi.nlm.nih.gov/pubmed/34596016 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.39.2100894 |
| _version_ | 1784577566173036544 |
|---|---|
| author | Martínez-Baz, Iván Trobajo-Sanmartín, Camino Miqueleiz, Ana Guevara, Marcela Fernández-Huerta, Miguel Burgui, Cristina Casado, Itziar Portillo, María Eugenia Navascués, Ana Ezpeleta, Carmen Castilla, Jesús Martín, Carmen Polo, Isabel Bacaicoa, Amaya Chamorro, Judith Vidán, Juana Estévez, Ingrid Tordoya, Igberto Quílez, Delia Lameiro, Francisco Álvaro, Ana Isabel Albéniz, Esther Echeverría, Aitziber López Moreno, Paula Gorricho, Javier Ardanaz, Eva Arriazu, Maite Baigorria, Fernando Barricarte, Aurelio de la Cruz, Enrique Díaz, Jorge Egüés, Nerea Cenoz, Manuel García Iriarte, Nerea Nekotxea, Kenya Moreno-Iribas, Conchi Sayón, Carmen Tellechea, Maitane Nuín, Marian |
| author_facet | Martínez-Baz, Iván Trobajo-Sanmartín, Camino Miqueleiz, Ana Guevara, Marcela Fernández-Huerta, Miguel Burgui, Cristina Casado, Itziar Portillo, María Eugenia Navascués, Ana Ezpeleta, Carmen Castilla, Jesús Martín, Carmen Polo, Isabel Bacaicoa, Amaya Chamorro, Judith Vidán, Juana Estévez, Ingrid Tordoya, Igberto Quílez, Delia Lameiro, Francisco Álvaro, Ana Isabel Albéniz, Esther Echeverría, Aitziber López Moreno, Paula Gorricho, Javier Ardanaz, Eva Arriazu, Maite Baigorria, Fernando Barricarte, Aurelio de la Cruz, Enrique Díaz, Jorge Egüés, Nerea Cenoz, Manuel García Iriarte, Nerea Nekotxea, Kenya Moreno-Iribas, Conchi Sayón, Carmen Tellechea, Maitane Nuín, Marian |
| author_sort | Martínez-Baz, Iván |
| collection | PubMed |
| description | COVID-19 vaccine effectiveness by product (two doses Comirnaty, Spikevax or Vaxzevria and one of Janssen), against infection ranged from 50% (95% CI: 42 to 57) for Janssen to 86% (70 to 93) for Vaxzevria-Comirnaty combination; among ≥ 60 year-olds, from 17% (−26 to 45) for Janssen to 68% (48 to 80) for Spikevax; and against hospitalisation from 74% (43 to 88) for Janssen to > 90% for other products. Two doses of vaccine were highly effective against hospitalisation, but suboptimal for infection control. |
| format | Online Article Text |
| id | pubmed-8485582 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Centre for Disease Prevention and Control (ECDC) |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84855822021-10-18 Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021 Martínez-Baz, Iván Trobajo-Sanmartín, Camino Miqueleiz, Ana Guevara, Marcela Fernández-Huerta, Miguel Burgui, Cristina Casado, Itziar Portillo, María Eugenia Navascués, Ana Ezpeleta, Carmen Castilla, Jesús Martín, Carmen Polo, Isabel Bacaicoa, Amaya Chamorro, Judith Vidán, Juana Estévez, Ingrid Tordoya, Igberto Quílez, Delia Lameiro, Francisco Álvaro, Ana Isabel Albéniz, Esther Echeverría, Aitziber López Moreno, Paula Gorricho, Javier Ardanaz, Eva Arriazu, Maite Baigorria, Fernando Barricarte, Aurelio de la Cruz, Enrique Díaz, Jorge Egüés, Nerea Cenoz, Manuel García Iriarte, Nerea Nekotxea, Kenya Moreno-Iribas, Conchi Sayón, Carmen Tellechea, Maitane Nuín, Marian Euro Surveill Rapid Communication COVID-19 vaccine effectiveness by product (two doses Comirnaty, Spikevax or Vaxzevria and one of Janssen), against infection ranged from 50% (95% CI: 42 to 57) for Janssen to 86% (70 to 93) for Vaxzevria-Comirnaty combination; among ≥ 60 year-olds, from 17% (−26 to 45) for Janssen to 68% (48 to 80) for Spikevax; and against hospitalisation from 74% (43 to 88) for Janssen to > 90% for other products. Two doses of vaccine were highly effective against hospitalisation, but suboptimal for infection control. European Centre for Disease Prevention and Control (ECDC) 2021-09-30 /pmc/articles/PMC8485582/ /pubmed/34596016 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.39.2100894 Text en This article is copyright of the authors or their affiliated institutions, 2021. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made. |
| spellingShingle | Rapid Communication Martínez-Baz, Iván Trobajo-Sanmartín, Camino Miqueleiz, Ana Guevara, Marcela Fernández-Huerta, Miguel Burgui, Cristina Casado, Itziar Portillo, María Eugenia Navascués, Ana Ezpeleta, Carmen Castilla, Jesús Martín, Carmen Polo, Isabel Bacaicoa, Amaya Chamorro, Judith Vidán, Juana Estévez, Ingrid Tordoya, Igberto Quílez, Delia Lameiro, Francisco Álvaro, Ana Isabel Albéniz, Esther Echeverría, Aitziber López Moreno, Paula Gorricho, Javier Ardanaz, Eva Arriazu, Maite Baigorria, Fernando Barricarte, Aurelio de la Cruz, Enrique Díaz, Jorge Egüés, Nerea Cenoz, Manuel García Iriarte, Nerea Nekotxea, Kenya Moreno-Iribas, Conchi Sayón, Carmen Tellechea, Maitane Nuín, Marian Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021 |
| title | Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021 |
| title_full | Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021 |
| title_fullStr | Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021 |
| title_full_unstemmed | Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021 |
| title_short | Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021 |
| title_sort | product-specific covid-19 vaccine effectiveness against secondary infection in close contacts, navarre, spain, april to august 2021 |
| topic | Rapid Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485582/ https://www.ncbi.nlm.nih.gov/pubmed/34596016 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.39.2100894 |
| work_keys_str_mv | AT martinezbazivan productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT trobajosanmartincamino productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT miqueleizana productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT guevaramarcela productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT fernandezhuertamiguel productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT burguicristina productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT casadoitziar productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT portillomariaeugenia productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT navascuesana productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT ezpeletacarmen productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT castillajesus productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT martincarmen productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT poloisabel productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT bacaicoaamaya productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT chamorrojudith productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT vidanjuana productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT estevezingrid productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT tordoyaigberto productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT quilezdelia productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT lameirofrancisco productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT alvaroanaisabel productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT albenizesther productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT echeverriaaitziber productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT lopezmorenopaula productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT gorrichojavier productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT ardanazeva productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT arriazumaite productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT baigorriafernando productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT barricarteaurelio productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT delacruzenrique productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT diazjorge productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT eguesnerea productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT cenozmanuelgarcia productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT iriartenerea productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT nekotxeakenya productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT morenoiribasconchi productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT sayoncarmen productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT tellecheamaitane productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 AT nuinmarian productspecificcovid19vaccineeffectivenessagainstsecondaryinfectioninclosecontactsnavarrespainapriltoaugust2021 |